USSTOCK.TODAY
Market Closed
Log in Sign up

Ensysce Biosciences Inc(ENSC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

ENSC
ENSC
Ensysce Biosciences Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$0.36
-0.01 ▼ -2.51%
Nov 19 at 7:11 PM ET (Korea 11/20 09:11)
$0.35
-0.01 ▼ -2.94%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -5.99Insider Own ⓘ 4.72%Shs Outstand ⓘ 19.5MPerf Week ⓘ -6.87%
Market Cap ⓘ 0.01BForward P/E ⓘ -EPS next Y ⓘ 89.89%Insider Trans ⓘ -Shs Float ⓘ 18.5MPerf Month ⓘ -30.65%
Enterprise Value ⓘ -0.02BPEG ⓘ -EPS next Q ⓘ -2.36Inst Own ⓘ 55.02%Short Float ⓘ 0.48%Perf Quarter ⓘ -3.4%
Income ⓘ -0.09BP/S ⓘ 1.13EPS this Y ⓘ 85.95%Inst Trans ⓘ 5.87%Short Ratio ⓘ 0.17Perf Half Y ⓘ 11.61%
Sales ⓘ 0.01BP/B ⓘ 0.26EPS next 5Y ⓘ 71.76%ROA ⓘ -533.26%Short Interest ⓘ 0.09MPerf YTD ⓘ -60.8%
Book/sh ⓘ 1.41P/C ⓘ 0.24EPS past 3/5Y ⓘ 87.61% -ROE ⓘ -635.44%52W High ⓘ -81.51% ($1.95)Perf Year ⓘ -80.3%
Cash/sh ⓘ 1.52P/FCF ⓘ -Sales past 3/5Y ⓘ 26.16% 5.21%ROIC ⓘ -331.65%52W Low ⓘ 56.78% ($0.23)Perf 3Y ⓘ -97.34%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 1.72%Gross Margin ⓘ -Volatility(W/M) ⓘ 11.54% 11.54%Perf 5Y ⓘ -99.99%
Dividend TTM ⓘ -EV/Sales ⓘ -3.69Sales Y/Y TTM ⓘ 37.91%Oper. Margin ⓘ -185.96%ATR (14) ⓘ 0.05Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 8EPS Q/Q ⓘ -250.18%Profit Margin ⓘ -1473.72%RSI (14) ⓘ 39.74Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 8Sales Q/Q ⓘ 342.43%SMA20 ⓘ -8.85% ($0.39)Beta ⓘ 1.09Target Price ⓘ $4.08
Payout ⓘ -Debt/Eq ⓘ 0.01Earnings ⓘ 2026/08/19SMA50 ⓘ -17.66% ($0.44)Rel Volume ⓘ 0.26Prev Close ⓘ $0.37
Employees ⓘ 10LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ -SMA200 ⓘ -10.34% ($0.4)Avg Volume(3M) ⓘ 0.53MPrice ⓘ $0.36
IPO ⓘ 2018/2/26Option/Short ⓘ No/YesTrades ⓘ 283Volume ⓘ 141,502Change ⓘ -2.51%
Company
ENSC ENSCEnsysce Biosciences Inc | NASD | Biotechnology Deep dive

💊 This is a clinical-stage pharmaceutical company developing next-generation painkillers with abuse-deterrent technology. It is researching new drug candidates designed to lower the abuse risk of opioids such as oxycodone, using its trypsin-activated TAAP platform and its overdose-prevention MPAR platform. The company has no commercialized products yet and remains a very small biotech that relies on its clinical-stage pipeline.

Quote

Over the past 1 year, on the lower side

82% below its 1-year high.

Now $0.36
52w low$0.2352w high$1.95
52W Range8%
Volume ⓘ 141,502

Traded less than usual. That is 26% of its average volume.

B
Overall · fairly good
We judged 7 of the 8 questions below. 4 rate excellent and 2 need caution.
Not applicable: dividends.
ETFs holding this stock 1 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #516 of 598 in the industry

Based on market cap of $7M.

FAQ

FAQ

What kind of company is ENSC?

ENSC belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ENSC?

The market cap of ENSC is approximately $7M, ranking 5,464 within its sector.

What is the 52-week high and low for ENSC?

ENSC has recorded a 52-week high of $1.95 and a low of $0.23.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels